This is the first study to demonstrate that the circ-SIRT1/EIF4A3/N-cadherin/vimentin axis promotes the proliferation and EMT of CRC cells, providing a novel therapeutic target and strategy for the treatment of this cancer. This evidence concerns the gene CDH2 and colorectal carcinoma.